Abstract
The role of complement in the development and regulation of antibody responses under both healthy and pathological conditions is known for long. Unraveling the elements involved and the molecular mechanisms underlying the events however is still in progress. This review focuses on the role of complement receptors CR1 (CD35) and CR2 (CD21) expressed on B lymphocytes, which interact with ligands generated upon activation of component C3, the major protein of the complement cascade. The binding and possible effects of immune complexes comprising antigen, antibody and complement on B-cell activation are discussed. Results of clinical studies of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis and conclusions drawn from animal models used to investigate various aspects of human diseases are also debated. We discuss similarities regarding the overall structure and certain functions of complement and complement receptors in mice and men however, call the attention to major differences regarding tissue distribution and their role in B-cell functions.
Keywords: complement, b cell, regulation, autoimmunity
Current Pharmaceutical Design
Title: Regulation of B-Cell Activation by Complement Receptors CD21 and CD35
Volume: 9 Issue: 23
Author(s): Anna Erdei, Jozsef Prechl, Andrea Isaak and Eszter Molnar
Affiliation:
Keywords: complement, b cell, regulation, autoimmunity
Abstract: The role of complement in the development and regulation of antibody responses under both healthy and pathological conditions is known for long. Unraveling the elements involved and the molecular mechanisms underlying the events however is still in progress. This review focuses on the role of complement receptors CR1 (CD35) and CR2 (CD21) expressed on B lymphocytes, which interact with ligands generated upon activation of component C3, the major protein of the complement cascade. The binding and possible effects of immune complexes comprising antigen, antibody and complement on B-cell activation are discussed. Results of clinical studies of autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis and conclusions drawn from animal models used to investigate various aspects of human diseases are also debated. We discuss similarities regarding the overall structure and certain functions of complement and complement receptors in mice and men however, call the attention to major differences regarding tissue distribution and their role in B-cell functions.
Export Options
About this article
Cite this article as:
Erdei Anna, Prechl Jozsef, Isaak Andrea and Molnar Eszter, Regulation of B-Cell Activation by Complement Receptors CD21 and CD35, Current Pharmaceutical Design 2003; 9 (23) . https://dx.doi.org/10.2174/1381612033454351
DOI https://dx.doi.org/10.2174/1381612033454351 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allosteric Targeting of Aurora A Kinase Using Small Molecules: A Step Forward Towards Next Generation Medicines?
Current Medicinal Chemistry Tetrahydrobioterin (BH4) Pathway: From Metabolism to Neuropsychiatry
Current Neuropharmacology The Many Faces of Glutathione Transferase Pi
Current Molecular Medicine Synthesis, Biological Evaluation and In Silico Study of β-Chloro Vinyl Chalcones as Inhibitors of the TNF-α, IL-6 With Anticancer and Antioxidant Activity
Letters in Drug Design & Discovery Docosahexaenoic Acid and Membrane Lipid Domains
Current Organic Chemistry SERMs: Evolutionary Chemistry, Revolutionary Biology
Current Pharmaceutical Design Protein Kinase Inhibitors for the Treatment of Inflammation - An Overview
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy Anti - TNF Therapy for Crohns Disease
Current Pharmaceutical Design Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis – Is There a Relationship?
Vascular Disease Prevention (Discontinued) Gold Salts Therapy in Respiratory Diseases
Current Respiratory Medicine Reviews Pharmacokinetics/Pharmacodynamics Model-Supported Early Drug Development
Current Pharmaceutical Biotechnology Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology Current Concepts in the Diagnosis and Treatment of Type 1 and Type 2 Autoimmune Pancreatitis
Recent Patents on Inflammation & Allergy Drug Discovery Opto-Acoustic Imaging of Drug Discovery Biomarkers
Current Pharmaceutical Biotechnology Current and Emerging Strategies in Osteoporosis Management
Current Pharmaceutical Design Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration
Current Medicinal Chemistry